BCLI(Delisted)
BrainStorm Cell·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BCLI
Brainstorm Cell Therapeutics Inc.
A leading developer of cellular therapies for neurodegenerative diseases
1325 Avenue of Americas, 28th Floor, New York, NY 10019
--
BrainStorm Cell Therapeutics Inc., was incorporated under the laws of Washington State on September 22, 2000 and re-incorporated in Delaware on November 15, 2006. The Company is a leading biotechnology company dedicated to the development and commercialization of best-in-class autologous cell therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis; progressive multiple sclerosis (" PMS "); Alzheimer's disease (" AD "); and neurodegenerative diseases. The Company's proprietary cell therapy platform, NurOwn, utilizes cell culture methods to induce autologous bone marrow mesenchymal stem cells (" MSCs ") to secrete high levels of neurotrophic factors (" NTFs "), modulate neuroinflammatory and neurodegenerative disease processes, promote neuron survival and improve neurological function.
Earnings Call
Q1/2025
Estimate EPS-0.97
Actual EPS-0.45
Estimate Revenue--
Actual Revenue--
Contradictions in Focus: BrainStorm Cell Therapeutics' 2025Q1 Earnings Call Reveals Key Challenges in Manufacturing, Funding, and Trial Strategy
May 19,2025 10:24
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BCLI has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.47, beating expectations. The chart below visualizes how BCLI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
